United Therapeutics (UTHR) Insider Notice: 3,000 Shares to be Sold

Rhea-AI Filing Summary

United Therapeutics Corp (UTHR) filing a Form 144 notifies a proposed sale of 3,000 common shares on 09/02/2025 through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $1,269,630.00. The shares were acquired the same day by stock option exercise and paid in cash. The filer reports no securities sold in the past three months and affirms they are unaware of undisclosed material adverse information. The notice includes standard Rule 144 and 10b5-1 representations.

Insights

Securities Compliance Analyst

TL;DR: Routine insider sale notice following option exercise; procedural compliance appears intact.

The Form 144 documents a same-day stock option exercise and immediate proposed sale of 3,000 common shares with an aggregate market value of $1,269,630. The use of a broker and the filing of Form 144 indicate the filer intends to comply with Rule 144 resale requirements. No prior sales in the past three months are reported, reducing aggregation concerns. There is no disclosure of undisclosed adverse information and no indication of a trading plan date for Rule 10b5-1 in the visible fields.

Corporate Governance Specialist

TL;DR: Procedural disclosure only; no material governance or control change disclosed.

The filing is limited to disclosure of a proposed sale following an option exercise. It does not show leadership changes, related-party transactions beyond the option exercise, or other governance actions. The representation about lack of material undisclosed information is standard. Investors receive a clear notice of insider selling activity, but the filing contains no additional corporate governance signals.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3000	1269630.00	45226262	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/02/2025	Stock Option Exercise	Issuer			3000	09/02/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did United Therapeutics (UTHR) disclose in this Form 144?

The filer disclosed a proposed sale of 3,000 common shares on 09/02/2025 via Morgan Stanley Smith Barney LLC with aggregate market value $1,269,630.00.

How were the UTHR shares acquired that are being sold?

The shares were acquired on 09/02/2025 through a stock option exercise, and payment was made in cash.

Did the filer report any securities sold in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Through which broker will the UTHR shares be sold and on which exchange?

The sale is to be executed by Morgan Stanley Smith Barney LLC on NASDAQ.

Does the filing indicate any undisclosed material information about United Therapeutics?

By signing, the filer represents they do not know any material adverse information that has not been publicly disclosed.